Drug Trial Radar · NCT00959569
Esmolol in Cardiac Surgery
Last checked: Nov 19, 2026Latest source record: Oct 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Aug 2009
Primary completion
May 2018
Study completion Jun 2018
Sponsor
- Lead sponsor
- Università Vita-Salute San RaffaeleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 14, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This large randomized double-blind clinical trial (esmolol vs placebo) will enroll patients undergoing cardiac surgery to study the additive cardiac protection of this therapeutic strategy.
Conditions
- Cardiac Surgery
Interventions
EsmololDrug
esmolol (1-3 mg/kg) during cardiac surgery
PlaceboDrug
normosaline (same ml of the study drug)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite endpoint of number of dead patients and/or number of patients requiring prolonged ICU stay.Time frame: Hospital stay (approximately 2 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vita-Salute University
Milan, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.